# GeoVax files for offering of 29,585,798 shares or substitute warrants

_Published Wednesday, November 4, 2026 at 8:19 AM EST · Capital · Latest · Tier 2 — Notable_

GeoVax Labs filed a preliminary prospectus on November 3 for an underwritten offering of 29,585,798 common shares, with pre-funded warrants available in place of shares. The clinical-stage biotechnology company develops vaccines and immunotherapies and identifies its GEO-MVA poxvirus vaccine candidate as its near-term development priority.

The prospectus uses an assumed price of $0.169 per share; the final price will be negotiated with underwriter E.F. Hutton. Securities cannot be sold until the registration statement becomes effective.

## Sources

- [SEC EDGAR](https://www.sec.gov/Archives/edgar/data/832489/000143774926034729/govx20261102_s1.htm)

---
Canonical: https://techandbusiness.org/newswire/xlzFjRZ2EgMZn4ScixU5UM
Published: 2026-11-04T13:19:03.429Z
Story chronology: 2026-11-03T00:00:00.000Z
Retrieved: 2026-11-04T22:01:08.907Z
Publisher: Tech & Business (techandbusiness.org)